Bryn Williams, chief executive officer of Kuecept, commented: “We are pleased to have completed our corporate name change to Kuecept and we feel that the new brand image better reflects the strategic plans and objectives of the business going forward. Our primary focus is towards the generation of new enabling drug delivery technologies to facilitate the development of poorly soluble and challenging pharmaceutical and biopharmaceutical activities. This strategy and direction is evident by our recent in-licensing of several drug delivery technologies, as well as significant investment in a dedicated Research and Innovation facility. The company looks forward to sharing these opportunities with its existing and future clients over the coming year.”

Kuecept is very careful to emphasise that Synectix Pharmaceutical Solutions Ltd was not bought by another company and will be operated by the same group of dedicated people its customers have already come to know and rely on.